Track Novartis AG — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Novartis AG NVS · Stock Open Novartis AG in new tab

160.50 USD
P/E
30.63
EPS
5.24
Yield
2.76%
Safety Score
67
P/B
8.14
ROE
24.33
Beta
0.45
Target Price
157.10 USD
Novartis AG logo

Novartis AG

🧾 Earnings Recap – Q3 2026

Novartis reported Q3 sales growth and core margin expansion, with the stock up 1.5% after earnings—within the roughly flat range. Full-year 2026 bottom-line guidance was raised, while management said meaningful acceleration in Pluvicto’s hormone-sensitive prostate cancer launch is more likely next year.

  • Sales increased 4% in constant currency and core operating income rose 10%; management cited margin expansion and raised full-year 2026 bottom-line guidance.
  • Priority brands grew 29%. Kisqali sales rose 37%, Kesimpta 22%, and Leqvio 63%.
  • Pluvicto grew 20% in constant currency, but US growth was 9%. Management described the hormone-sensitive prostate cancer launch as being in its early days and expects further acceleration next year.
  • Kisqali’s early breast cancer launch was approved in 84 countries and reimbursed in 43; management reported 55% first-line new-patient share for Kisqali in US metastatic disease.
  • Leqvio’s US sales grew 60%; its share in Medicare reached 22%, according to management.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 3, 2027
P/E30.63
EPS5.24
Book Value19.71
Price to Book8.14
Debt/Equity128.61
% Insiders0.020%
Growth
Revenue Growth0.05%
Earnings Growth-0.69%
Estimates
Forward P/E16.16
Forward EPS9.93
Target Mean Price157.10
Dividend
Dividend Yield2.76%
Annual dividends4.53 USD
Ex-Div. DateMarch 11, 2026
Payout89.56%
5y avg Yield3.64%

DCF valuation

Model fair value for Novartis AG (NVS)
Result
Sign in to run the valuation for NVS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus Hold · mean target 157.10 USD (low 130.00, high 185.00) · as of 14 Nov 2026
Low 130.00
Mean 157.10
High 185.00
Price 160.50
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Novartis AG Logo Novartis AG Analysis (NVS)

Switzerland Health Care Official Website Stock

Is Novartis AG a good investment? Novartis AG (NVS) is currently trading at 160.50 USD. Market analysts have a consensus price target of 157.10 USD. This suggests the asset is currently trading above analyst expectations.

In terms of valuation, the stock trades at a P/E ratio of 30.63. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Novartis AG is expected to release its next earnings report on Feb. 3, 2027. The market consensus estimate for Forward EPS is 9.93.

For income investors, Novartis AG pays a dividend yield of 2.76%. With a payout ratio of 90%, the dividend appears to be under pressure.

Investor FAQ

Does Novartis AG pay a dividend?

Yes, it pays an annual dividend of 4.53 USD (2.76% yield).

What asset class is Novartis AG?

Novartis AG is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 3, 2027. The company currently has a trailing EPS of 5.24.

Company Profile

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Exchange Ticker
NYQ (United States) NVS
Trades
Dividend Yield
2.76%
5y avg 3.64%
Annual Dividends
4.53USD
Next Ex. Div Date
March 11, 2026
Payout Ratio
89.56%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2027
4.94 USD
March 16, 2027 (estimated) 4.9422
▸2026
4.74 USD
March 16, 2026 4.7403
▸2025
3.99 USD
April 25, 2025 3.9940
▸2024
7.52 USD
Sept. 24, 2024 3.7772
April 19, 2024 3.7400
▸2023
3.50 USD
March 20, 2023 3.4987
▸2022
3.33 USD
March 17, 2022 3.3253
▸2021
3.20 USD
March 15, 2021 3.1991
▸2020
3.09 USD
March 12, 2020 3.0874
▸2019
2.57 USD
March 13, 2019 2.5672
▸2018
2.67 USD
April 25, 2018 2.6676
▸2017
2.46 USD
April 20, 2017 2.4606
▸2016
2.47 USD
April 15, 2016 2.4749
▸2015
2.52 USD
April 20, 2015 2.5242
▸2014
2.72 USD
April 10, 2014 2.7186
▸2013
2.27 USD
April 5, 2013 2.2670
▸2012
2.20 USD
April 5, 2012 2.2043
▸2011
2.36 USD
April 8, 2011 2.3634
▸2010
1.95 USD
April 13, 2010 1.9484
▸2009
1.54 USD
April 6, 2009 1.5412
▸2008
1.54 USD
April 11, 2008 1.5375
▸2007
0.97 USD
April 10, 2007 0.9686
▸2006
0.89 USD
April 3, 2006 0.8942
▸2005
0.86 USD
April 6, 2005 0.8635
▸2004
0.72 USD
March 30, 2004 0.7222
▸2003
0.63 USD
April 7, 2003 0.6272
▸2002
0.47 USD
April 22, 2002 0.4677
▸2001
0.45 USD
April 20, 2001 0.4498
▸2000
1.77 USD
Nov. 14, 2000 0.9660
May 11, 2000 0.8024
▸1999
0.95 USD
May 24, 1999 0.9526
▸1998
0.84 USD
May 19, 1998 0.8364
▸1997
3.91 USD
May 15, 1997 0.6806
March 19, 1997 3.2340
Upcoming Dividends
Name Payment Date Status Amount
Novartis AG Mar 16, 2026 4.74025 USD
Stock Splits
Split Date Split Ratio to 1
May 11, 2000 2:1
April 9, 2019 1.116
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion